It is a pharma public limited company based in Fatehpur Roshnai, Uttar Pradesh, India, established in 2020.
2020 | Fatehpur Roshnai, Uttar Pradesh, India | ActiveEris Pharmaceuticals Limited, a active public limited company, was established on 02 June 2020 in Fatehpur Roshnai, Uttar Pradesh, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U33100UP2020PLC128964. Registered under ROC Roc Kanpur. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Inderjeet Singh Negi (Director), Kaushal Kamlesh Shah (Director), Sachin Shah (Director). Past directors included Mohit Vaid, Sripat Vaid, Inderjeet Singh Negi. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Arazi No. 1554, Vill Sachendi, Kalpi Road, Fatehpur Roshnai, Uttar Pradesh, 209304.
U33100UP2020PLC128964
128964
02 June 2020
₹1.00 M
₹0.10 M
Roc Kanpur
Unlisted
Active
Explore comprehensive insights into Eris Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Inderjeet Singh Negi | Director | 30 Jul 2024 | Current |
| Kaushal Kamlesh Shah | Director | 30 Jul 2024 | Current |
| Sachin Shah | Director | 30 Jul 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 30 Jul 2024 | Past |
| Pramod Abcsdd | Director | 30 Jul 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Director | 30 Jul 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Eris Pharmaceuticals Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 375% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1900%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Eris Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Eris Pharmaceuticals has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Eris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eris Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Eris Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Inderjeet Singh Negi was appointed as a Director was appointed as a Director on 30 Jul 2024 & has been associated with this company since 1 year 4 months . was recorded as a recent event.
The activity Kaushal Kamlesh Shah was appointed as a Director was appointed as a Director on 30 Jul 2024 & has been associated with this company since 1 year 4 months . was completed.
The activity Sachin Shah was appointed as a Director was appointed as a Director on 30 Jul 2024 & has been associated with this company since 1 year 4 months . was completed.
The activity Eris Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Kanpur. was completed.
The activity Eris Pharmaceuticals Limited was registered on 02 Jun 2020 with Roc Kanpur & aged 5 years 6 months as per MCA records. was completed.
The CIN of Eris Pharmaceuticals Limited is U33100UP2020PLC128964.
Eris Pharmaceuticals Limited is headquartered at Arazi No. 1554, Vill Sachendi, Kalpi Road, Fatehpur Roshnai, Uttar Pradesh, 209304.
Eris Pharmaceuticals Limited was incorporated on 02 June 2020.
The current directors of Eris Pharmaceuticals Limited are
The primary industry of Eris Pharmaceuticals Limited is Trade.
Eris Pharmaceuticals Limited is unlisted.
The authorized capital of Eris Pharmaceuticals Limited is ₹1.00 M, and the paid-up capital is ₹0.10 M.
The compliance status of Eris Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX